209 related articles for article (PubMed ID: 24072044)
1. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.
Karpova D; Dauber K; Spohn G; Chudziak D; Wiercinska E; Schulz M; Pettit AR; Levesque JP; Romagnoli B; Patel K; Chevalier E; Dembowsky K; Bonig H
Leukemia; 2013 Dec; 27(12):2322-31. PubMed ID: 24072044
[TBL] [Abstract][Full Text] [Related]
2. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
3. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 and mobilization of hematopoietic precursors.
Rettig MP; Ramirez P; Nervi B; DiPersio JF
Methods Enzymol; 2009; 460():57-90. PubMed ID: 19446720
[TBL] [Abstract][Full Text] [Related]
5. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
[TBL] [Abstract][Full Text] [Related]
6. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003.
Abraham M; Biyder K; Begin M; Wald H; Weiss ID; Galun E; Nagler A; Peled A
Stem Cells; 2007 Sep; 25(9):2158-66. PubMed ID: 17525235
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
9. Adrenaline administration promotes the efficiency of granulocyte colony stimulating factor-mediated hematopoietic stem and progenitor cell mobilization in mice.
Chen C; Cao J; Song X; Zeng L; Li Z; Li Y; Xu K
Int J Hematol; 2013 Jan; 97(1):50-7. PubMed ID: 23224606
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys.
Fang X; Fang X; Mao Y; Ciechanover A; Xu Y; An J; Huang Z
Stem Cell Res Ther; 2021 Jan; 12(1):17. PubMed ID: 33413613
[TBL] [Abstract][Full Text] [Related]
11. Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.
Di Giacomo F; Lewandowski D; Cabannes E; Nancy-Portebois V; Petitou M; Fichelson S; Romeo PH
Haematologica; 2012 Apr; 97(4):491-9. PubMed ID: 22180429
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation.
Winkler IG; Pettit AR; Raggatt LJ; Jacobsen RN; Forristal CE; Barbier V; Nowlan B; Cisterne A; Bendall LJ; Sims NA; Lévesque JP
Leukemia; 2012 Jul; 26(7):1594-601. PubMed ID: 22266913
[TBL] [Abstract][Full Text] [Related]
13. Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis.
Zhang J; Ren X; Shi W; Wang S; Chen H; Zhang B; Wang Z; Zhou Y; Chen L; Zhang R; Lv Y; Zhou J; Nan X; He L; Yue W; Li Y; Pei X
Blood; 2014 Jan; 123(3):428-41. PubMed ID: 24196072
[TBL] [Abstract][Full Text] [Related]
14. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
Paganessi LA; Walker AL; Tan LL; Holmes I; Rich E; Fung HC; Christopherson KW
Exp Hematol; 2011 Mar; 39(3):384-90. PubMed ID: 21168468
[TBL] [Abstract][Full Text] [Related]
15. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
[TBL] [Abstract][Full Text] [Related]
16. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.
Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H
Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853
[TBL] [Abstract][Full Text] [Related]
18. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice.
Brasel K; McKenna HJ; Charrier K; Morrissey PJ; Williams DE; Lyman SD
Blood; 1997 Nov; 90(9):3781-8. PubMed ID: 9345066
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.
Karpova D; Bräuninger S; Wiercinska E; Krämer A; Stock B; Graff J; Martin H; Wach A; Escot C; Douglas G; Romagnoli B; Chevalier E; Dembowski K; Hooftman L; Bonig H
J Transl Med; 2017 Jan; 15(1):2. PubMed ID: 28049490
[TBL] [Abstract][Full Text] [Related]
20. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
Ramirez P; Rettig MP; Uy GL; Deych E; Holt MS; Ritchey JK; DiPersio JF
Blood; 2009 Aug; 114(7):1340-3. PubMed ID: 19571319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
